The impact of cocaine use on outcomes in HIV-infected patients receiving buprenorphine/naloxone

Journal of Acquired Immune Deficiency Syndromes

Volumn 56, Issue SUPPL. 1, 2011, Pages

  Sullivan, Lynn E ^a   Botsko, Michael ^a   Cunningham, Chinazo O ^a   O'Connor, Patrick G ^a   Hersh, David ^b   Mitty, Jennifer ^c   Lum, Paula J ^d   Schottenfeld, Richard S ^e   Fiellin, David A ^a,f  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Center for HIV Educational Studies and Training   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

buprenorphine; cocaine; heroin dependence; HIV; opioid related disorders

Indexed keywords

ANTIRETROVIRUS AGENT; BUPRENORPHINE PLUS NALOXONE; COCAINE; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COCAINE DEPENDENCE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG TRAFFIC; FEMALE; FOLLOW UP; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; ANTI-HIV AGENTS; BUPRENORPHINE; COCAINE-RELATED DISORDERS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NALOXONE; NARCOTIC ANTAGONISTS; NEEDLE SHARING; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; UNSAFE SEX;

EID: 79951791597     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182097576     Document Type: Article

References (41)

1. Edlin BR, Irwin KL, Faruque S, et al. Intersecting epidemics-crack cocaine use and HIV infection among inner-city young adults. Multicenter Crack Cocaine and HIV Infection Study Team. N Engl J Med. 1994;331: 1422-1427.
2. Leri F, Bruneau J, Stewart J. Understanding polydrug use: review of heroin and cocaine co-use. Addiction. 2003;98:7-22. (Pubitemid 36044332)
3. Hubbard RL, Craddock SG, Flynn PM, et al Overview of 1-year follow-up outcomes in the Drug Abuse Treatment Outcome Study (DATOS). Psychol Addict Behav. 1997;11:261-278. (Pubitemid 28046589)
4. Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349:949-958. (Pubitemid 37064768)
5. Marsch LA, Stephens MA, Mudric T, et al. Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence. Exp Clin Psychopharmacol. 2005;13:293-302. (Pubitemid 43011154)
6. Camacho LM, Bartholomew NG, Joe GW, et al. Gender, cocaine and during-treatment HIV risk reduction among injection opioid users in methadone maintenance. Drug Alcohol Depend. 1996;41:1-7. (Pubitemid 26185289)
7. Di Poggio AB, Fornal F, Paparelli A, et al. Comparison between heroin and heroin-cocaine polyabusers: a psychopathological study. Ann NY Acad Sci. 2006;1074:438-445. (Pubitemid 44532849)
8. Grella CE, Anglin MD, Wugalter SE. Cocaine and crack use and HIV risk behaviors among high-risk methadone maintenance clients. Drug Alcohol Depend. 1995;37:15-21.
9. Grella CE, Anglin MD, Wugalter SE. Patterns and predictors of cocaine and crack use by clients in standard and enhanced methadone maintenance treatment. Am J Drug Alcohol Abuse. 1997;23:15-42. (Pubitemid 27087583)
10. Schottenfeld RS, Chawarski MC, Pakes JR, et al. Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence. Am J Psychiatry. 2005;162:340-349. (Pubitemid 40216216)
11. Maremmani I, Pani PP, Mellini A, et al. Alcohol and cocaine use and abuse among opioid addicts engaged in a methadone maintenance treatment program. J Addict Dis. 2007;26:61-70. (Pubitemid 46797096)
12. Williamson A, Darke S, Ross J, et al. The effect of persistence of cocaine use on 12-month outcomes for the treatment of heroin dependence. Drug Alcohol Depend. 2006;81:293-300. (Pubitemid 43152456)
13. McCance-Katz EF, Jatlow P, Rainey PM. Effect of cocaine use on methadone pharmacokinetics in humans. Am J Addict. 2010;19:47-52.
14. McCance-Katz EF, Rainey PM, Moody DE. Effect of cocaine use on buprenorphine pharmacokinetics in humans. Am J Addict. 2010;19: 38-46.
15. Sofuoglu M, Gonzalez G, Poling J, et al. Prediction of treatment outcome by baseline urine cocaine results and self-reported cocaine use for cocaine and opioid dependence. Am J Drug Alcohol Abuse. 2003;29: 713-727. (Pubitemid 37549402)
16. Sullivan LE, Moore BA, O'Connor PG, et al. The association between cocaine use and treatment outcomes in patients receiving office-based buprenorphine/naloxone for the treatment of opioid dependence. Am J Addict. 2010;19:53-58.
17. Cunningham CO, Sohler NL, Berg KM, et al. Type of substance use and access to HIV-related health care. AIDS Patient Care STDs. 2006;20: 399-407. (Pubitemid 43993094)
18. Cejtin HE, Komaroff E, Massad LS, et al. Adherence to colposcopy among women with HIV infection. J Acquir Immune Defic Syndr. 1999; 22:247-252. (Pubitemid 30012668)
19. Sohler NL, Wong MD, Cunningham WE, et al. Type and pattern of illicit drug use and access to health care services for HIV-infected people. AIDS Patient Care STDs. 2007;21 Suppl 1:S68-S76.
20. Palacio H, Shiboski CH, Yelin EH, et al. Access to and utilization of primary care services among HIV-infected women. J Acquir Immune Defic Syndr. 1999;21:293-300. (Pubitemid 29357660)
21. Metsch LR, McCoy HV, McCoy CB, et al. Use of health care services by women who use crack cocaine. Women Health. 1999;30:35-51.
22. Metsch LR, Pereyra M, Brewer TH. Use of HIV health care in HIV-seropositive crack cocaine smokers and other active drug users. J Subst Abuse. 2001;13:155-167. (Pubitemid 38209968)
23. Kalichman SC, Graham J, Luke W, et al. Perceptions of health care among persons living with HIV/AIDS who are not receiving antiretroviral medications. AIDS Patient Care STDs. 2002;16:233-240. (Pubitemid 34478163)
24. Sharpe TT, Lee LM, Nakashima AK, et al. Crack cocaine use and adherence to antiretroviral treatment among HIV-infected black women. J Community Health. 2004;29:117-127. (Pubitemid 39012830)
25. Ingersoll K. The impact of psychiatric symptoms, drug use, and medication regimen on non-adherence to HIV treatment. AIDS Care. 2004;16:199-211. (Pubitemid 38183583)
26. Crisp BR, Williams M, Timpson S, et al. Medication compliance and satisfaction with treatment for HIV disease in a sample of African-American crack cocaine smokers. AIDS Behav. 2004;8:199-206. (Pubitemid 38888113)
27. Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Genl Intern Med. 2002;17:377-381. (Pubitemid 34626108)
28. Moss AR, Hahn JA, Perry S, et al. Adherence to highly active antiretroviral therapy in the homeless population in San Francisco: a prospective study. Clin Infect Dis. 2004;39:1190-1198. (Pubitemid 40169319)
29. Tucker JS, Burnam MA, Sherbourne CD, et al. Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. Am J Med. 2003;114:573-580. (Pubitemid 36577260)
30. Webber MP, Schoenbaum EE, Gourevitch MN, et al. A prospective study of HIV disease progression in female and male drug users. AIDS. 1999;13: 257-262. (Pubitemid 29050414)
31. Vlahov D, Celentano DD. Access to highly active antiretroviral therapy for injection drug users: adherence, resistance, and death. Cad Saúde Pública. 2006;22:705-718.
32. Galai N, Vlahov D, Margolick JB, et al. Changes in markers of disease progression in HIV-1 seroconverters: a comparison between cohorts of injecting drug users and homosexual men. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;8:66-74.
33. Vlahov D, Galai N, Safaeian M, et al. Effectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodeficiency virus infection. Am J Epidemiol. 2005;161:999-1012. (Pubitemid 40734348)
34. Ling W, Charuvastra C, Collins JF, et al. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction. 1998;93:475-486. (Pubitemid 28188067)
35. Fiellin DA, Pantalon MV, Chawarski MC, et al. Buprenorphine maintenance in primary care: a randomized controlled trial of counseling conditions and medication dispensing. N Engl J Med. 2006;355:365-374.
36. Sullivan LE, Barry D, Moore BA, et al. A trial of integrated buprenorphine/naloxone and HIV clinical care. Clin Infect Dis. 2006; 43(Suppl 4):S184-190. (Pubitemid 44901886)
37. Weiss L, Egan JE, Botsko M, et al. A multisite evaluation of integrated buprenorphine/naloxone and HIV treatment: overview of the BHIVES collaborative. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S7-S13.
38. Mannheimer SB, Mukherjee R, Hirschhorn LR, et al. The CASE adherence index: A novel method for measuring adherence to antiretroviral therapy. AIDS Care. 2006;18:853-861. (Pubitemid 44395534)
39. McLellan AT, Luborsky L, Woody GE, et al. An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. J Nerv Ment Dis. 1980;168:26-33. (Pubitemid 10187569)
40. Fiellin DA, Sullivan LE, Egan JE, et al. Drug treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/nalox-one. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S33-S38.
41. McCance-Katz EF, Rainey PM, Moody DE. Effect of cocaine use on buprenorphine pharmacokinetics in humans. Am J Addict. 2010;19:38-46.